首先，中美经贸磋商提升市场预期，但地缘局势扰动市场神经。上周中美双方在英国举行了新一轮 经贸磋商，这是上周四两国元首电话沟通之后的迅速工作跟进，高效的协调进程有利于缓解市场的担 忧。当然。近期国内资本市场重心缓慢上移，也已经部分定价了该预期。临近周末，中东地区地缘事件 成为扰动市场神经的重要边际变量。上周五，亚太地区的股市大都由此而产生些许调整，不过总体调整 幅度不大，国内股市仍有自我稳定的韧性。 上周，两市震荡微跌，成交再次回升。沪指上周来回拉锯，周中高点接近五月中旬的高点，但最终 小幅调整，沪指收盘跌破五天均线。深圳成指上周围绕 60 天均线反复争夺，周五收盘未能收复该均 线。量能方面，上周两市日均量能超过了 13000 亿，连续两周回升。上周市场热点主要集中在上游资源 品和医药行业。投资风格方面，中小盘风格跌幅更大，大盘蓝筹相对抗跌。 从市场运行节奏看，沪指反身向上，但在 5 月中旬的高点附近遇到阻力。沪指于 5 月中旬逐步向下 调整，呈现高低点同步下移特征。但最终在 60 天均线获得支撑后，重新展开了一波反弹，上周在接近 5 月中旬的高点后，遇阻回落。这提示我们，去年四季度的成交密集区以及今年一季度的 ...

Market Overview - The overall market declined last week, with the Wind All A Index and the CSI A500 both down by 0.27% [1] - The average daily trading volume in the market increased to 1.37 trillion, showing a week-on-week rise [1] Industry Performance - In the CITIC primary industry sectors, non-ferrous metals, petroleum and petrochemicals, and pharmaceuticals led the gains, while food and beverage, computers, and building materials saw declines [1] Trade Relations - The first meeting of the China-US economic and trade consultation mechanism was held in London, with a framework agreement reached to implement the consensus from the June 5 call between the two countries' leaders [1] - The US expressed a desire to reach a resolution with China regarding rare earth issues, and China has approved some export license applications related to rare earths [1] - Overall, the dialogue mechanism between China and the US is progressing in an orderly manner, with manageable short-term market impacts [1] Geopolitical Risks - The sixth round of nuclear talks between Iran and the US scheduled for the 15th has been canceled, leading to heightened tensions in the Middle East and escalating geopolitical risks [1] Domestic Macro Data - In domestic macroeconomic data, May exports grew by 4.8% year-on-year, but exports to the US saw a significant decline of 34.5% [2] - Both CPI and PPI showed negative year-on-year growth in May, indicating that inflation levels are still in a bottoming phase [2] - M1 growth reached 2.3%, the highest in nearly a year, while M2 growth remained stable, indicating overall liquidity is maintained [2] International Macro Data - In the US, May CPI data was below market expectations for the fourth consecutive month, and PPI showed moderate increases, suggesting mild inflationary pressures [2] - President Trump continues to pressure the Federal Reserve for interest rate cuts, with an announcement regarding the next Fed chair expected soon [2] Investment Opportunities - The ongoing geopolitical tensions may create short-term market volatility, but there could be "correction opportunities" following any mispricing [2] - Investors are advised to focus on stable income-generating assets such as the 10-year Treasury ETF, cash flow ETF, and dividend state-owned enterprise ETF [2]

Group 1 - The 2025 Technology Finance and Industry Innovation Conference was held in Shanghai, focusing on the integration of innovation chains and industrial chains, and the role of technology finance in empowering industrial upgrades [1] - The Shanghai Stock Exchange aims to deepen reforms and enhance the adaptability of its system to support technological and industrial innovation, with plans to innovate low-volatility fund products and diversify asset allocation tools for investors [1] Group 2 - The ESG performance of small home appliance companies is becoming a critical dimension for assessing their long-term value, but the overall ESG disclosure rate among 22 listed companies in the sector is low, with significant disparities in environmental investment and governance structures [2] - Key issues such as customer service, product safety, and information security are gaining market attention, indicating a strategic value in improving ESG performance for future development [2] Group 3 - Recent regulatory actions have halted high-interest automotive finance practices, which were initially seen as beneficial but have led to consumer rights violations and market disorder [3] - The automotive finance market is expected to return to its service-oriented nature, leveraging technology and differentiated competition for healthy development [3] Group 4 - Several actively managed pharmaceutical equity funds have reported returns exceeding 60% this year, with a general optimistic outlook on the innovative drug sector, although some experts caution about potential valuation risks [4] - Institutions are exploring new investment directions for the second half of the year, particularly in AI and consumer sectors [4] Group 5 - The recent policy allowing companies from the Guangdong-Hong Kong-Macao Greater Bay Area to list on the Shenzhen Stock Exchange is seen as a key measure for financial collaboration and supporting the real economy [5] - The return of quality tech companies from Hong Kong to A-shares is expected to enhance investor confidence in China's capital market [5] Group 6 - As of June 15, 10 A-share listed companies have released their half-year performance forecasts, with 8 expecting year-on-year growth in net profit, including companies like Zhongce Rubber Group and Ying Shi Innovation Technology [8] - The number of newly established index-enhanced funds has surged by approximately 438% year-on-year, driven by policy support and investor demand [8] Group 7 - In May, New Hope sold 1.3339 million pigs, showing a month-on-month decrease of 16.42% and a year-on-year decrease of 2.41%, while Wen's shares sold 3.1554 million pigs, with a year-on-year increase of 32.64% [9] - Despite a decline in sales, the pig farming sector has remained profitable for 12 consecutive months, with expectations of stable price fluctuations in the industry [9]

Group 1 - Middle Eastern stock markets experienced a significant decline on Sunday, while oil prices surged in early Asian trading on Monday, and gold prices increased, indicating volatility in the commodities market [1] - China's social financing increased by 2.29 trillion yuan in May, with new RMB loans amounting to 620 billion yuan and new RMB deposits nearing 2.18 trillion yuan, suggesting a tightening of the M2-M1 spread [1] - The State Council is researching measures to optimize the procurement of drugs and medical supplies, emphasizing the need to advance the construction of "good houses" [1] Group 2 - Ongoing military exchanges between Iran and Israel, with Iran considering a blockade of the Strait of Hormuz, while Israel attacked Iran's largest gas field [1] - Israeli Prime Minister stated that Israel is willing to cease actions if Iran agrees to abandon its nuclear program as per U.S. demands [1] - Reports indicate a failed assassination attempt on a senior Houthi leader by Israel, which the Houthi forces denied [1] Group 3 - The UK Prime Minister announced that there are no "obstacles" remaining to finalize the US-UK trade agreement [1] - A phone call between Japan and the US agreed to accelerate ministerial-level consultations to reach a mutually beneficial agreement, with Japan stating that the deadline of July 9 for the Basent has not been extended [1] - Upcoming release of China's May industrial output and retail sales data is anticipated [1]

Group 1 - The geopolitical conflict in the Middle East has significant implications but limited actual impact on Chinese assets, leading to a sudden change in risk appetite [1] - High consensus sectors with elevated valuations and trading volumes are likely to experience increased volatility, while the trend towards AI and strong industrial sectors will strengthen [1] - The focus is shifting back to policy signals, with persistently low price signals potentially acting as a new catalyst, requiring patience [1] Group 2 - The recent conflict between Israel and Iran may induce short-term disturbances in the A-share market, but the substantive impact is expected to be minimal [2] - Defensive sectors such as oil, gas, and precious metals may present better investment opportunities in the short term [2] - Historical data suggests that industries with favorable earnings forecasts tend to perform well, particularly in the context of the A-share market [2] Group 3 - Historically, conflicts in the Middle East have had minimal impact on A-shares and Hong Kong stocks, and the current situation is not expected to differ significantly [3] - The low share of the Middle East in China's import and export trade indicates that the conflict's effect on the domestic economy is weak [3] - The market may adopt a "wait and see" approach, focusing on existing main lines while observing the conflict's duration for future investment decisions [3] Group 4 - Recent negotiations between the US and China have eased trade tensions, but escalating geopolitical conflicts are impacting market risk appetite [4] - The upcoming Lujiazui Forum is expected to unveil significant financial policies, which could provide structural opportunities in the A-share market [4] - The domestic economy is anticipated to show resilience due to ongoing policy support, despite external uncertainties [4] Group 5 - The technology growth sector is becoming increasingly prominent in the market, with recent conflicts providing potential buying opportunities [6] - The internal factors, such as the outcomes of US-China negotiations and stable domestic economic performance, are crucial for market trends [6] - The technology sector remains in a high cost-performance zone, supported by industry trends and improving fundamentals [6] Group 6 - The market is currently experiencing a short-term adjustment phase, with high trading density leading to lower short-term returns [7] - Despite external disturbances, the long-term revaluation of Chinese assets is ongoing, with a focus on low-density, high-potential sectors [7] - Investment strategies should consider stable dividend stocks and sectors with lower trading density but strong industrial catalysts [7] Group 7 - The regional conflict is likely to have a pulse-like impact on the market, with the core issue being the structural nature of the market [8] - The stability of capital market policies is providing a buffer against macro disturbances, allowing for a focus on strong sectoral trends [8] - The technology sector's recovery is expected to depend on breaking through existing structural barriers [8] Group 8 - The A-share market is anticipated to gradually rise due to supportive fiscal policies and improved liquidity conditions [9] - Key investment opportunities are identified in sectors such as innovative pharmaceuticals, consumer services, and AI applications [9] - The market's upward movement is contingent on the development of new industries and the overall economic environment [9] Group 9 - The AH premium index has recently dropped to its lowest level in five years, indicating potential for further convergence [10] - Factors influencing the AH premium include the liquidity of the Hong Kong market and the quality of listed companies [10] - The trend suggests that the AH premium may continue to narrow, with potential for more Hong Kong stocks to outperform A-shares [11] Group 10 - The recent US-China negotiations have met market expectations, but geopolitical tensions are causing short-term fluctuations in the A-share market [12] - The core factors affecting A-shares remain structural issues rather than external events, with a focus on economic fundamentals and policy developments [12] - The upcoming Lujiazui Forum is seen as a critical window for observing significant financial policies that could support market stability [12]

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, rating it as "Overweight" [2][21]. Core Insights - The pharmaceutical sector saw a weekly increase of 1.4%, outperforming the Shanghai Composite Index, which decreased by 0.2% [3][4]. - The overall valuation of the pharmaceutical sector is at 30.0 times PE for 2025E, ranking fifth among 31 primary industries [4][9]. - Significant collaborations and developments include a strategic partnership between CSPC and AstraZeneca worth over $5.3 billion, focusing on the discovery and development of new oral candidates for various diseases [10]. - The NDA for the high-selectivity small molecule inhibitor Pimicotinib by HeYue Pharma has been accepted, marking a significant milestone for the company [10]. - A successful clinical trial for an invasive brain-machine interface in China indicates advancements in technology that could improve the quality of life for patients with spinal injuries and amputations [11]. Market Performance - The weekly performance of the pharmaceutical sector shows a 1.4% increase, ranking fifth among 31 sub-industries [3][4]. - The breakdown of performance across various sub-sectors includes: - Chemical preparations (+4.0%) - Medical R&D outsourcing (+4.8%) - Raw materials (+0.9%) - Vaccines (-3.3%) - Offline pharmacies (-2.5%) [4][5]. Key Events - CSPC and AstraZeneca's collaboration includes an upfront payment of $110 million, with potential milestone payments totaling up to $16.2 billion for R&D and $3.6 billion for sales [10]. - The acceptance of the NDA for Pimicotinib is a notable achievement for HeYue Pharma, as it is their first project entering the NDA approval process [10]. - The successful clinical trial of the brain-machine interface positions China as the second country globally to enter this clinical trial phase [11]. Investment Analysis - The report highlights the rapid growth in product revenue and licensing deals in the innovative drug sector over the past three years, suggesting a trend of expanding interest in innovative drug companies and related CXO companies [10]. - Companies to watch include: - HengRui Medicine - BeiGene - WuXi AppTec - Kelun Pharmaceutical [10].

Investment Rating - The industry rating is "Outperform the Market" indicating that the overall return of the industry is expected to exceed the market benchmark index by more than 5% in the next 6 to 12 months [79]. Core Insights - The report highlights a significant increase in bidding data for medical equipment, with monthly bidding amounts showing year-on-year growth rates ranging from 41% to 113% from December 2024 to May 2025, suggesting a robust demand recovery [4][17]. - The report emphasizes the strong performance of innovative drugs, with companies like China Biopharma and Rongchang Bio continuing to see positive developments, supported by government policies optimizing drug procurement [5][41]. - The medical device sector is expected to experience a turning point in financial reporting in Q2 and Q3 2025, as the effects of increased bidding data begin to reflect in company revenues [4][26]. Summary by Sections 1. Weekly Performance Review - The CITIC Medical Index rose by 1.5% during the week of June 9-13, 2025, outperforming the CSI 300 Index by 1.8 percentage points, ranking third among CITIC's primary industry classifications [3][41]. - The top five performing stocks for the week included Yiming Pharmaceutical (+38.49%), Saiseng Pharmaceutical (+36.35%), and Aoyang Health (+35.01%) [59]. 2. Equipment Bidding Data - Bidding amounts for medical equipment have shown a consistent increase, with May 2025 seeing a 69% year-on-year growth, indicating a strong recovery in demand [4][17]. - The report predicts that the financial results for companies involved in equipment installation will begin to reflect this demand surge in Q2 2025, while inventory companies may see performance improvements by Q3 2025 [4][26]. 3. Mid to Long-term Investment Strategy - The report suggests focusing on three main themes: innovation, recovery, and policy support. It highlights the potential for innovative drugs and medical devices to drive growth, particularly in companies with strong international competitiveness [5][6]. - Specific companies to watch include Union Medical, Shanhai Mountain, and Mindray Medical, which are expected to benefit from the ongoing recovery in bidding data and demand [4][6][27].

在复杂的国际政治经济棋局中，美国正悄然布置新的战略，利用关税手段迫使印度在军事采购和国际组织参与等关键领域作出 重大调整。最近，美国商务部长霍华德·卢特尼克的言论揭示了背后更深层的战略意图，展现了美国新的外交方向。 除了在军事采购领域向美国靠拢，印度还面临着来自外界的压力，特别是在是否继续留在金砖组织的问题上。在美国的影响 下，印度国内有声音认为，作为金砖成员国，参与一些活动可能会妨碍与美国关系的改善。卢特尼克也暗示，印度在金砖组织 中的立场正在成为美印关系中的一个敏感点，特别是印度对美元霸权的某些看法，这让美国非常不满。他指出，印度在金砖内 部推动"卢比结算"等去美元化的提案，遭遇了俄罗斯和沙特等国的拒绝，结果印度反倒成为去美元化过程中的最大受害者。面 对这一困境，美国在背后施加压力，暗示印度若想改善与美国的经济和战略关系，就必须重新审视其在金砖组织中的角色。 长期以来，印度对俄罗斯军事装备的依赖，一直是阻碍美印关系深化的一个关键因素。随着美国加大对俄罗斯公司的制裁，以 及全球合作伙伴越来越面临与莫斯科关系疏远的压力，印度的采购战略正受到前所未有的审视。在此背景下，美国提出的贸易 协议，无疑成为了一剂"双刃 ...

金融工程 | 金工定期报告 金融工程 证券研究报告 基金季报（T 期）披露有股票持仓的证监会行业配置信息，基金最近（T-1 期）半年报、年报会披露全部股票持仓，可得基金半年报、年报末非重仓 股持仓信息。假设基金非重仓股持仓在两期各行业下持股种类不变，仅持 股权重按比例变化，那么根据 T-1 期非重仓股持仓按比例放缩权重可得到 T 期非重仓股模拟持仓。 基金风格配置监控周报： 权益基金连续两周上调小盘股票仓位 公募基金风格监控 2025 年 06 月 15 日 作者 吴先兴 分析师 SAC 执业证书编号：S1110516120001 wuxianxing@tfzq.com 基金季报中披露有基金前十大重仓股，同时企业季度报告中披露有企业的 前十大股东信息（主要使用上市公司 1、3 季度十大股东信息），结合这两 部分信息我们可以得到基金持仓更加详细的重仓股信息。因此模拟全部股 票持仓只需要估计基金剩余的非重仓持股明细。 韩乾 分析师 SAC 执业证书编号：S1110522100001 hanqian@tfzq.com 相关报告 1 《金融工程：金融工程-因子跟踪周 报：盈利、分红因子表现较好 -20250614》 ...

《通知》还包括，要完善医药购销领域行贿人、受贿人"黑名单"制度和不良单位记录制度。落实对业务 指导的医药行业社会组织督促职责，规范兼职取酬、期刊管理、会议举办，严格分支机构设立审批，积 极引导行业组织提升专业化水平和公信力。 6月13日，国家卫生健康委、教育部、工业和信息化部、公安部等14部委联合发布《关于印发2025年纠 正医药购销领域和医疗服务中不正之风工作要点的通知》。（下称《通知》） 《通知》共分为4个部分15项内容，提出要持续深化医药购销领域治理，紧盯"关键少数"和关键岗位， 聚焦药品、高值医用耗材、医用设备、基建和信息化项目招投标、后勤服务等监管重点，持续规范检测 样本外送、外配处方、项目审批、资金使用等关键环节行为，加大行政执法和司法办案力度。 近年来，国家卫健委等部委已多次联合制定印发了"纠正医药购销领域和医疗服务中不正之风工作要点 的通知"。 《关于印发2023年纠正医药购销领域和医疗服务中不正之风工作要点的通知》提出，切实推进全行 业"受贿行贿一起查"，落实规纪法衔接的部门主体责任。在医药产品销售采购领域，整治医药生产企业 及与之关联的经销商、医药代表，以各种名义或形式实施"带金销售"，给 ...